# A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

> **NCT06270706** · PHASE1 · RECRUITING · sponsor: **Pliant Therapeutics, Inc.** · enrollment: 124 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumor

## Interventions

- **DRUG:** PLN-101095
- **DRUG:** PLN-101095
- **DRUG:** PLN-101095
- **DRUG:** PLN-101095
- **DRUG:** PLN-101095
- **DRUG:** PLN-101095
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06270706
- **Lead sponsor:** Pliant Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-30
- **Primary completion:** 2030-06
- **Final completion:** 2030-06
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06270706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06270706, "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06270706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*